Jack Thompson

Jack Thompson

Auto-generated profile, based on publicly available information

Jack Thompson

Guy's and St Thomas' NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
EMEmma F Magavern
Emma F Magavern
MMMaia Megase
Maia Megase
JTJack Thompson
Jack Thompson
GMGabriel Marengo
Gabriel Marengo
JJJulius Jacobsen
Julius Jacobsen
MCMark J. Caulfield
Mark J. Caulfield
Background: Adverse drug reactions (ADRs) harm patients and are costly for healthcare systems. Genetic variation contributes to variability in medication response and prospective knowledge of these variants can decrease risk of ADRs, as shown in the PREPARE trial. Reduction in ADRs would affect only those reactions to drugs contained in well-validated pharmacogene–drug pairs. The scope of ADRs represented by these drugs on a population scale is unclear. The objective of this study was to characterize the pharmacogene–drug-associated ADR reporting landscape from a national regulatory pharmacovigilance dataset to elucidate the scale of potential ADR mitigation by pharmacogenomics (PGx) implementation. Methods and findings: All publicly available Yellow Card ADR reports to the United Kingdom Medicines and Healthcare Products Regulatory Agency, from 1963 to 2024, were compiled using programmatic data extraction. The ADRs were analysed with descriptive statistics, stratified by PGx status and by associated genes. Prescribing prevalence from the literature was compared with age range matched ADR reports for PGx-associated drugs. There were 1,345,712 ADR reports, attributed to 2,499 different substances. 115,789 adverse drug reports (9%) were associated with drugs for which ADR risk can be modified based on pharmacogenomic prescribing guidance. Seventy-five percent of these (n = 87,339) were due to medicines which interact with only three pharmacokinetic pharmacogenes (CYP2C19, CYP2D6, SLCO1B1). Forty-seven percent of all the PGx mitigatable ADRs identified were attributed to psychiatric medications (n = 54,846), followed by 24% attributed to cardiovascular medications (n = 28,279). Those experiencing PGx mitigatable ADRs, as compared with non-PGx mitigatable ADRs, were older and the ADRs more often consisted of severe non-fatal reactions. Many PGx-associated psychiatric drug ADRs were overrepresented as compared with prescribing prevalence, but fatal cardiac arrhythmias were uncommon consequences, comprising only 0.4% of these ADRs (n = 172 of n = 48,315 total ADRs). Limitations of this data source include under reporting of ADRs and reporting bias. These findings are based on analysis of the Yellow Card dataset described and may not represent all ADRs from a generalised patient population. Conclusions: Nine percent of all reported ADRs are associated with drugs where a genetic variant can cause heightened risk of an ADR and inform prescribing. A panel of only three pharmacogenes could potentially mitigate three in every four PGx modifiable ADRs. Based on our findings, Psychiatry may be the single highest impact specialty to pilot PGx to reduce ADRs and associated morbidity, mortality and costs.

28 October 2024 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
JTJack T. Thompson
Jack T. Thompson
DWDavid M. Wood
David M. Wood
PDPaul I. Dargan
Paul I. Dargan

2 July 2026 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
DCDharmisha Chauhan
Dharmisha Chauhan
DCDello Russo Cinzia
Dello Russo Cinzia
JTJack Thompson
Jack Thompson
DHDyfrig Hughes
Dyfrig Hughes
KPKatherine Payne
Katherine Payne
MPMunir Pirmohamed
Munir Pirmohamed
Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy. However, it is also used off‐label across a range of gastrointestinal malignancies and in rare malignancies such as glioblastoma and sarcomas. The pegylated formulation is licensed for use as combination therapy in adult patients with metastatic pancreatic adenocarcinoma. Irinotecan is hydrolysed to its active metabolite, SN‐38, which is predominantly inactivated by the enzyme uridine diphosphate glucuronosyltransferase UGT1A1. UGT1A1 is encoded by the gene UGT1A1 , which is polymorphically expressed, with allele frequencies varying across populations. Poor metabolizers carry two variants that reduce UGT1A1 enzyme expression or activity, leading to increased risk of irinotecan toxicity. Any patient who is about to be prescribed irinotecan for an epithelial malignancy should have pharmacogenetic testing, to identify clinically relevant UGT1A1 variants, where testing is available. Irinotecan dose should be reduced by 30% at Cycle 1 treatment in poor metabolizers for all indications, with doses titrated thereafter based on tolerability and neutrophil counts. The lack of evidence precludes us from making any recommendation for rare malignancies such as sarcomas. Our guideline is consistent with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk–benefit profile, ensuring that therapy is optimized to maximize benefits while minimizing potential harms.

3 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JTJack Tandy Thompson
Jack Tandy Thompson
MMMaia Megase
Maia Megase
MBMarta Boffito
Marta Boffito
MCMark Caulfield
Mark Caulfield
EMEmma F Magavern
Emma F Magavern
Background: Metabolomics has potential to enhance definition of medication response phenotypes in early phase clinical trials, yet global uptake and distribution are not well characterised. This study provides an international assessment of metabolomics integration in registered early phase clinical trials.Methods: Data were obtained from the World Health Organization’s International Clinical Trials Registry Platform (ICTRP). Early phase trials (phase 0–2) conducted from 2010 to 2025 were analysed, and metabolomics studies were identified using predefined keyword searches across trial records.Findings: A total of 183,041 early phase trials were identified, of which 640 (0.35%) incorporated metabolomics. Uptake has increased modestly over time but remains low overall and is concentrated predominantly in high-income countries. The United Kingdom demonstrated the highest proportional integration (1.3%), while the People’s Republic of China (n=237) and the United States of America (n=90) contributed the greatest absolute number of trials with metabolomics. Among included metabolomic studies: 187 (29.2%) were phase 0, 229 (35.8%) were phase 1 trials, 183 (28.6%) were phase 2, and 41 (6.4%) were combined phase 1/2 studies. Metabolomics was most commonly included as a secondary or exploratory outcome (69.1%). Interpretation: Metabolomics remains underutilised in early phase clinical trials and is primarily employed as a discovery tool rather than used to identify biomarkers for clinical endpoints. Addressing barriers to implementation will be critical to enable broader integration of metabolomics into early phase clinical trials and to integrate a multi-omic approach to precision medicine.

2 September 2024
Verified
Preprint
Open access
JTJack Thompson
Jack Thompson
DTDavid Wood (Antidotes Ti)
David Wood (Antidotes Ti)
PDPaul Dargan
Paul Dargan
Not-yet-known not-yet-known not-yet-known unknown In 2015, the United States Food and Drug Administration (FDA) approved uridine triacetate to treat overdose and severe toxicity of the fluoropyrimidine chemotherapy agents 5-fluorouracil (5-FU) and its oral prodrug capecitabine. Uridine triacetate is as an oral prodrug of uridine which competes with cytotoxic fluoropyrimidine metabolites for incorporation into nucleotides. Two million people worldwide start fluoropyrimidine chemotherapy each year with 20-30% developing severe or life-threatening adverse effects, often attributable to a genetic predisposition such as dihydropyrimidine dehydrogenase deficiency. Whilst genetic pre-screening is recommended prior to starting fluoropyrimidine agents, this only prevents 20-30% of early-onset life-threatening toxicity and so does not obviate the need for an antidote. Initial in-human studies established that uridine triacetate more than doubles the maximum tolerated weekly 5-FU bolus dose . A lack of clinical equipoise meant a placebo-controlled phase-III trial was not ethical and so the phase-III trials used historical controls. These found that uridine triacetate improved survival in those with fluoropyrimidine overdose and severe toxicity from 16% to 94%, with 34% able to resume chemotherapy within 30days. Five case reports of delayed fluoropyrimidine toxicity demonstrate improvement following uridine triacetate treatment 120-504 hours after last fluoropyrimidine administration suggesting efficacy beyond the FDA licensing indications. Mechanistically uridine triacetate would be expected to be effective for overdose and severe toxicity of Tegafur (a 5-FU prodrug), but there are no published case reports describing this. Uridine triacetate is available internationally through an expanded access scheme and has been available in the UK since 2019 on a named patient basis.